Chinese expert consensus statement on dual antiplatelet therapy in patients with coronary artery disease

reviews the most remarkable paper published in the Journal over the last 3 months.Dual antiplatelet therapy (DAPT) based on aspirin and a platelet P2Y 12 inhibitor is the cornerstone of pharmacological treatment aimed at preventing cardiac and systemic ischaemic events in patients with coronary artery disease (CAD). 1 In recent years, with updated drugeluting stents, the application of potent P2Y 12 inhibitor and the continuous development of drug combination strategies, the clinical option and decision-making surrounding DAPT have changed greatly.Referring to the latest international guidelines 2-5 and combining these with the characteristics of Chinese patients with CAD, a guideline writing committee comprised of: the Atherosclerosis and Coronary Heart Disease Working Group; the Interventional Cardiology Working Group of the Chinese Society of Cardiology; the Specialty Committee on Prevention and Treatment of Thrombosis; the Specialty Committee on Coronary Artery Disease and Atherosclerosis of the Chinese College of Cardiovascular Physicians; as well as the Editorial Board of CJC, have formulated the first Chinese expert consensus on DAPT for CAD patients to standardize the application of DAPT and improve the clinical benefits of antithrombotic therapy by minimizing the risk of ischaemic and bleeding complications. 6This article aims to briefly introduce the content of the expert consensus.